英加韦林(Ingavirin) - 在研适应症：病毒感染，流感病毒感染，中性粒细胞减少_专利_临床

概要

基本信息

药物类型

小分子化药

别名

IMIDAZOLYL ETHANAMIDE PENTANDIOIC ACID、Vitaglutam

+ [2]

靶点-

作用机制

细胞凋亡抑制剂、粒细胞刺激剂、造血刺激剂

+ [1]

治疗领域

感染血液及淋巴系统疾病呼吸系统疾病

在研适应症

病毒感染流感病毒感染中性粒细胞减少

非在研适应症

急性放射综合征急性呼吸道感染骨髓抑制+ [6]

原研机构

Valenta Pharmaceuticals JSC

在研机构

Valenta Pharmaceuticals JSC

非在研机构

Myelo Therapeutics GmbHBausch Health Americas, Inc.

最高研发阶段批准上市

首次获批日期

俄罗斯 (2009-01-01),

流感病毒感染中性粒细胞减少

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C10H15N3O3

InChIKeyKZIMLUFVKJLCCH-UHFFFAOYSA-N

CAS号219694-63-0

关联

9

项与英加韦林相关的临床试验

NCT06315400 / Recruiting临床4期

Double-blind, Multicenter, Randomized, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of Ingavirin®, 60 mg Capsules in the Treatment of Influenza and Other Acute Respiratory Viral Infections in Children Aged 13-17 Years.

The study is planned to evaluate the therapeutic efficacy and safety of Ingavirin®, capsules, 60 mg, in the treatment of influenza or other acute respiratory infections in children from 13 to 17 years compared with placebo.

开始日期2023-12-19

申办/合作机构

Valenta Pharmaceuticals JSC

NCT05216497 / Completed临床3期

Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19

The primary objective of this study is to investigate the efficacy of Ingavirin®, 90 mg capsules in achieving clinical improvement of novel coronavirus disease (COVID-19) symptoms. A secondary goal of this study is to evaluate the safety of Ingavirin®, 90 mg capsules in patients with COVID-19 infection.

开始日期2021-10-06

申办/合作机构

Valenta Pharmaceuticals JSC

NCT05269290 / Completed临床3期

A Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children Aged 6 Months to 2 Years With Influenza and Other Acute Respiratory Viral Infections Against Standard Therapy

The study is planned to evaluate the therapeutic efficacy and safety of Ingavirin®, syrup, 30 mg/5 ml, in the treatment of influenza or other acute respiratory infections in children from 6 months to 2 years compared with placebo.

开始日期2021-09-23

申办/合作机构

Valenta Pharmaceuticals JSC

100 项与英加韦林相关的临床结果

登录后查看更多信息

100 项与英加韦林相关的转化医学

登录后查看更多信息

100 项与英加韦林相关的专利（医药）

登录后查看更多信息

37

项与英加韦林相关的文献（医药）

2023-12-01·Molecular Diversity

Insight into the Hantaan virus RNA-dependent RNA polymerase inhibition using in-silico approaches

Article

作者: Sharaf, Mohamed ; Abdalla, Mohnad ; Badshah, Syed Lal ; Faisal, Shah

The Hantaan virus (HTN) is a member of the hantaviridae family. It is a segmented type, negative-strand virus (sNSVs). It causes hemorrhagic fever with renal syndrome, which includes fever, vascular hemorrhage, and renal failure. This illness is one of the most serious hemorrhagic diseases in the world, and it is a major public health concern due to its high mortality rate. The Hantaan virus RNA-dependent RNA polymerase complex (RdRp) is involved in viral RNA transcription and replication for the survival and transmission of this virus. Therefore, it is a primary target for antiviral drug development. Interference with the endonucleolytic "cap-snatching" reaction by the HTN virus RdRp endonuclease domain is a particularly appealing approach for drug discovery against this virus. This RdRp endonuclease domain of the HTN virus has a metal-dependent catalytic activity. We targeted this metal-dependent enzymatic activity to identify inhibitors that can bind and disrupt this endonuclease enzyme activity using in-silico approaches i.e., molecular docking, molecular dynamics simulation, predicted absorption, distribution, metabolism, excretion, toxicity (ADMET) and drug-likeness studies. The docking studies showed that peramivir, and ingavirin compounds can effectively bind with the manganese ions and engage with other active site residues of this protein. Molecular simulations also showed stable binding of these ligands with the active site of HTN RdRp. Simulation analysis showed that they were in constant contact with the active site manganese ions and amino acid residues of the HTN virus endonuclease domain. This study will help in better understanding the HTN and related viruses.

2020-01-01·Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti

Ingavirin might be a promising agent to combat Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2).

Article

作者: Padrtova, Tereza ; Kovac, Gustav ; Hudecova, Lucia ; Malík, Ivan

The Severe Acute Respiratory Coronavirus 2 (SARS--CoV-2) and Coronavirus Disease-19 (COVID-19) pandemic, caused by the virus, have changed the world in just half a year. Lack of effective treatment, coupled with etiology of COVID-19, has resulted in more than 500,000 confirmed deaths at the time of writing, and the global economy is at an unseen unprecedented low level with unknown near- and long-term consequences. Ingavirin has been considered a non-toxic broad-spectrum antiviral with a complex mechanism of action. The molecule was originally designed for the prophylaxis and treatment of flu caused by both Influenza A and B viruses and for the treatment of viral causes of acute respiratory illness. The article hypothesized that the efficiency of given 1H-imidazol-4-yl heterocyclic scaffold-containing compound against SARS-CoV-2 might be connected with its ability to interfere with specific heterogeneous nuclear ribonucleoproteins (A1, for example). These specific cellular RNA-binding proteins showed affinity to Severe Acute Respiratory Coronavirus (SARS-CoV) nucleocapsid (N) protein, which shared high homology with the N protein of SARS-CoV-2 and the fact was expressed by a sequence identity of 90.52%. Impairing of the interactions between nuclear ribonucleoproteins and nucleocapsid (N) protein of SARS-CoV-2 might result in the inhibition of a viral replication cycle. Additional immunomodulating properties of ingavirin could be favorable for induction of adaptive immunity of host cells.

2013-01-01·Terapevticheskii arkhiv4区 · 医学

[Current principles in the chemoprophylaxis of acute respiratory viral infections].

4区 · 医学

ArticleOA

作者: Liapina, E P ; Shul'diakov, A A ; Kuznetsov, V I

AIMTo evaluate the preventive efficacy of the Russian antiviral drug ingavirin (vitaglutam) in the epidemiological foci with the peak incidence of acute respiratory viral infections (ARVI).SUBJECTS AND METHODSFour hundred men and women aged 18 to 65 years from the epidemic foci of ARVI who had been in close daily contact with the patients whose diagnosis was verified by laboratory tests were examined. Two hundred persons received prophylaxis with ingavirin (a 90-mg oral capsule once daily for 7 days) and 200 took placebo according to the same scheme. The efficiency index and coefficient were calculated and the relative risk of the disease was estimated to evaluate the efficiency of ARVI prevention. A pharmacoeconomic analysis was made.RESULTSThere is evidence that the administration of 90-mg ingavirin capsules (OAO "Valenta Farm", Russia) caused a reduction in morbidity rates among those who had been in contact by 63% and in the risk of ARVI by 2.7 times. There was a reduction in the duration of fever by one day and a milder course of respiratory disease in the ingavirin-treated contact persons who developed ARVI.CONCLUSIONIngavirin meets all requirements for current drugs for the nonspecific prevention of ARVI at the peak of its incidence. It has a pronounced protective effect and broad-spectrum activity, low toxicity and high safety, which allows it to be recommended for the emergency intrafocal prevention at the peak of the incidence of influenza and ARVI in adults.

100 项与英加韦林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J05AX	DB11944

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
病毒感染	俄罗斯	Valenta Pharmaceuticals JSC	2014-07-17
流感病毒感染	俄罗斯	-	2009-01-01
中性粒细胞减少	俄罗斯	-	2009-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床2期	俄罗斯	Valenta Pharmaceuticals JSC	2021-10-06
骨髓抑制	临床2期	德国	Myelo Therapeutics GmbH	2016-03-01
乳腺癌	临床2期	德国	Myelo Therapeutics GmbH	2016-03-01
宫颈上皮内瘤样病变	临床2期	德国	Myelo Therapeutics GmbH	2016-03-01
化疗引起的发热性中性粒细胞减少症	临床2期	德国	Myelo Therapeutics GmbH	2016-03-01
急性呼吸道感染	临床2期	俄罗斯	Valenta Pharmaceuticals JSC	2010-10-03
普通感冒	临床2期	俄罗斯	Valenta Pharmaceuticals JSC	2010-10-03
普通感冒	临床2期	俄罗斯	Bausch Health Americas, Inc.	2010-10-03
流感病毒感染	临床2期	俄罗斯	Valenta Pharmaceuticals JSC	2010-10-03
病毒性呼吸道感染	临床2期	俄罗斯	Valenta Pharmaceuticals JSC	2010-10-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2020	临床2期	化疗引起的骨髓抑制	-	IEPA	(餘鬱壓鑰遞觸醖鏇簾憲) = reduced 鬱觸餘壓鏇簾蓋簾選鬱 (齋網觸構鬱顧願淵鹽壓 ) 更多	-	2020-05-25
				IEPA (Control)
NCT02692742 (ASCO2019) 人工标引	临床2期	乳腺癌	130	Myelo001	製鹽淵鬱遞願鏇鑰齋網(繭衊繭選鬱積膚壓鏇獵) = 鑰觸淵壓餘鬱選觸鏇製壓構製繭齋襯醖範憲糧 (範簾觸構積壓蓋襯構觸, 12.6 ~ 14.5) 更多	积极	2019-05-31
				placebo	製鹽淵鬱遞願鏇鑰齋網(繭衊繭選鬱積膚壓鏇獵) = 簾獵淵衊窪觸顧選壓醖壓構製繭齋襯醖範憲糧 (範簾觸構積壓蓋襯構觸, 13.0 ~ 14.9) 更多